8-K: Kodiak Sciences' Zenkuda Shines in GLOW2 Diabetic Retinopathy Study

Kodiak Sciences announced positive topline results from its GLOW2 Phase 3 study, demonstrating Zenkuda's superiority over sham in diabetic retinopathy treatment.

Summary

• Zenkuda achieved superiority over sham in GLOW2, with 62.5% of treated patients showing a 2-step improvement in Diabetic Retinopathy Severity Score (DRSS) compared to 3.3% of sham-treated patients (p<0.0001).
• Demonstrated an 85% risk reduction in the key secondary endpoint of developing sight-threatening complications (2.4% with Zenkuda vs 15.8% with sham, p=0.0001).
• 13.7% of Zenkuda-treated patients achieved a 3-step improvement in DRSS versus 0% with sham (p<0.0001).
• Efficacy was strong and independent of concomitant GLP-1 receptor agonist use, with 60.0% of GLP-1 users and 64.3% of non-users achieving a 2-step DRSS improvement.
• Zenkuda demonstrated a favorable safety profile with a 0% intraocular inflammation rate and a 2.3% cataract adverse event rate (vs 1.6% with sham).
• The positive results support a multi-indication Biologics License Application (BLA)-ready profile for Zenkuda, leading to an acceleration of BLA submission plans.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive announcement, demonstrating strong efficacy and safety for Zenkuda in a pivotal Phase 3 study, significantly advancing its regulatory pathway and pipeline prospects.

Positives

• Zenkuda demonstrated statistically significant superiority over sham in the primary endpoint, with 62.5% of patients achieving a 2-step DRSS improvement (p<0.0001).
• Achieved an 85% risk reduction in sight-threatening complications, reinforcing previous GLOW1 study findings.
• Showed a 3-step DRSS improvement in 13.7% of patients, significantly better than sham (0%).
• Maintained strong efficacy regardless of concomitant GLP-1 medication use, supporting its utility in a real-world diabetic patient population.
• Exhibited a favorable safety profile with 0% intraocular inflammation and low cataract rates (2.3% vs 1.6% sham).
• The enhanced commercial formulation and Antibody Biopolymer Conjugate (ABC) Platform safety profile were strongly supported by the data.
• Zenkuda now has a multi-indication BLA-ready profile, leading to accelerated BLA submission plans.
• The study successfully expanded the patient population to include those with proliferative diabetic retinopathy (PDR) and mild diabetic macular edema (DME).
• All patients were on 6-month dosing intervals by the end of the study, indicating strong durability.

Risks

• The completed Phase 3 studies for Zenkuda may not be sufficient to support a BLA submission or approval in diabetic retinopathy, retinal vein occlusion, or wet AMD.
• A BLA for tarcocimab tedromer or any other product candidate may not be accepted by, or receive approval from, the FDA or foreign regulatory agencies when expected, or at all.
• Cessation, modification, or delay of any ongoing clinical studies and Kodiak's development of Zenkuda, KSI-501, KSI-101, or any other product candidate may occur.
• Safety, efficacy, and durability data observed in Kodiak's product candidates in current or prior studies may not continue or persist.
• KSI-501 may not inhibit VEGF and IL-6 or have an impact on the treatment of patients as expected, and preclinical data suggesting the possibility that KSI-501 may be a disease-modifying therapy may not translate to clinical outcomes.
• The DAYBREAK Phase 3 study for Zenkuda or KSI-501 may not achieve its primary endpoint or may not do so on the anticipated timeline.
• The PEAK Phase 3 study for KSI-101 may not achieve its primary endpoint or may not do so on the anticipated timeline.
• Any one or more of Kodiak's product candidates may not be successfully developed, approved, or commercialized.
• Kodiak's research and development efforts and ability to advance product candidates into later stages of development may fail.
• Adverse conditions in the general domestic and global economic markets may significantly impact Kodiak's business and operations.

Future Outlook

Kodiak Sciences intends to accelerate its Biologics License Application (BLA) submission timeline for Zenkuda, leveraging its multi-indication BLA-ready profile in diabetic retinopathy, retinal vein occlusion, and wet AMD. The company also anticipates potential BLA submissions for KSI-501 in wet AMD after the DAYBREAK study readout (expected 3Q2026) and for KSI-101 in Macular Edema Secondary to Inflammation (MESI) after the PEAK study readout (expected 4Q2026), assuming successful outcomes.

Management Comments

• "GLOW2 is unique among registration trials targeting an approval for DR by intentionally including eyes with center-involved DME and proliferative DR. Among this higher-risk population, Zenkuda showed strong efficacy while incorporating a 6-month treatment interval after three monthly injections, supporting flexible dosing as may be clinically indicated." Dr. Charles Wykoff, Chairman of Research, Retina Consultants of America.
• "GLOW2 is also unique in having no restrictions on GLP-1 agonist use, reflecting real-world patient medication use, and patients benefited equally from Zenkuda treatment regardless of concomitant use." Dr. Charles Wykoff.
• "The strong outcomes in GLOW2 are likely driven by thoughtful refinements to both regimen and formulation. An additional Week 4 loading dose may have strengthened early control of disease, while the enhanced formulation was designed to deliver a rapid initial effect together with long-lasting durability enabled by its ABC design." Dr. J. Pablo Velazquez-Martin, Chief Medical Officer of Kodiak Sciences.
• "We now have a multi-indication BLA-ready profile for Zenkuda, and we intend to accelerate our BLA submission plans." Dr. Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences.
• "GLOW2 is the first Phase 3 study to test Zenkuda’s enhanced commercial formulation, which combines free (unconjugated) and conjugated protein in a single biologic. The favorable safety data no cases of IOI reported and low, balanced cataract incidence across both arms further support the safety profile of the ABC Platform." Dr. Victor Perlroth.
• "Having three different investigational therapies being explored in four different Phase 3 studies with three readouts expected in 2026 is very special and the result of hard work." Dr. Victor Perlroth.

Industry Context

StockSavvy.ai notes that current diabetic retinopathy treatment guidelines are largely reactive, often initiated only after irreversible retinal damage. Zenkuda's strong efficacy, particularly with a 6-month dosing interval, addresses the significant treatment burden of frequent injections that limits broader anti-VEGF utilization in non-proliferative DR. The study's inclusion of GLP-1 users reflects real-world patient populations, a crucial factor given the growing use of these therapies in diabetes management. Zenkuda's performance in a higher-risk population (PDR and mild DME) further positions it as a potentially transformative therapy, offering durable disease control across a wide spectrum of diabetic retinopathy patients.

Comparison to Industry Standards

• Zenkuda's mean ocular half-life of 20 days is approximately three times longer than approved anti-VEGF therapies, suggesting superior durability and less frequent dosing.
• The 6-month dosing interval achieved in GLOW2 for all patients significantly reduces treatment burden compared to existing anti-VEGF therapies, which often require more frequent injections (e.g., aflibercept's label dosing typically involves monthly or bi-monthly injections for initial treatment).
• Zenkuda demonstrated an 85% risk reduction in sight-threatening complications in GLOW2, which is substantially higher than the approximately 50% risk reduction generally observed with anti-VEGF therapy compared to laser or no treatment for DR progression.
• The 0% intraocular inflammation rate is a strong safety indicator, as intraocular inflammation can be a concern with some intravitreal injections.
• The inclusion of patients with PDR and mild DME in GLOW2 expands the scope beyond typical non-proliferative DR trials, addressing a higher-risk population effectively.

Stakeholder Impact

• Shareholders: Positive impact due to successful clinical trial results, accelerated BLA submission, and strengthened pipeline, potentially leading to increased market value.
• Patients: Potential for a new, highly effective, and durable treatment option for diabetic retinopathy, reducing treatment burden and preventing vision-threatening complications.
• Physicians: Zenkuda offers a flexible dosing regimen (up to 6-month intervals) and strong efficacy across a wide spectrum of DR patients, including those with PDR and mild DME, potentially shifting treatment paradigms.

Next Steps

• Accelerate Biologics License Application (BLA) submission for Zenkuda.
• Full end-of-study results to be presented at an upcoming congress by Dr. Charles Wykoff.
• Anticipate potential BLA submission for KSI-501 in wet AMD after DAYBREAK study primary endpoint readout (expected 3Q2026).
• Anticipate potential BLA submission for KSI-101 in Macular Edema Secondary to Inflammation (MESI) after PEAK study pivotal analysis 1 readout (expected 4Q2026).
• Continue DAYBREAK, PEAK, and PINNACLE Phase 3 studies.

Key Dates

Recommendation

The overwhelmingly positive Phase 3 GLOW2 results for Zenkuda, demonstrating superiority over sham, significant risk reduction in sight-threatening complications, and a favorable safety profile with extended durability, position Kodiak Sciences for an accelerated multi-indication BLA submission. This success validates the ABC Platform and de-risks the broader pipeline, including KSI-501 and KSI-101, which have upcoming readouts. The potential to address a $15 billion market with a differentiated product that reduces treatment burden makes this a compelling investment opportunity.

Keywords

Diabetic Retinopathy, Zenkuda, tarcocimab tedromer, Phase 3, GLOW2, anti-VEGF, Kodiak Sciences, biotechnology, retina, BLA, FDA, clinical trial, ocular, ABC Platform, GLP-1, sight-threatening complications, DRSS, PDR, DME, retinal vascular disease